- Home
- PRT vs CVM Comparison
PRT vs CVM Comparison
Compare PRT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- CVM
- Stock Information
- Founded
- PRT 2017
- CVM 1983
- Country
- PRT United States
- CVM United States
- Employees
- PRT N/A
- CVM N/A
- Industry
- PRT Oil & Gas Production
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRT Energy
- CVM Health Care
- Exchange
- PRT Nasdaq
- CVM Nasdaq
- Market Cap
- PRT 45.4M
- CVM 40.1M
- IPO Year
- PRT N/A
- CVM 1987
- Fundamental
- Price
- PRT $4.09
- CVM $0.40
- Analyst Decision
- PRT
- CVM
- Analyst Count
- PRT 0
- CVM 0
- Target Price
- PRT N/A
- CVM N/A
- AVG Volume (30 Days)
- PRT 67.2K
- CVM 2.0M
- Earning Date
- PRT 11-13-2024
- CVM 01-13-2025
- Dividend Yield
- PRT 10.37%
- CVM N/A
- EPS Growth
- PRT N/A
- CVM N/A
- EPS
- PRT 0.42
- CVM N/A
- Revenue
- PRT $6,059,380.00
- CVM N/A
- Revenue This Year
- PRT N/A
- CVM N/A
- Revenue Next Year
- PRT N/A
- CVM $152.91
- P/E Ratio
- PRT $9.63
- CVM N/A
- Revenue Growth
- PRT N/A
- CVM N/A
- 52 Week Low
- PRT $3.26
- CVM $0.36
- 52 Week High
- PRT $4.76
- CVM $3.08
- Technical
- Relative Strength Index (RSI)
- PRT 63.51
- CVM 38.00
- Support Level
- PRT $3.52
- CVM $0.37
- Resistance Level
- PRT $4.24
- CVM $0.42
- Average True Range (ATR)
- PRT 0.19
- CVM 0.04
- MACD
- PRT 0.06
- CVM -0.00
- Stochastic Oscillator
- PRT 80.39
- CVM 11.83
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.